[1]周振 江洪.脂肪组织在心房颤动中的研究进展[J].心血管病学进展,2023,(3):224.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.008]
 ZHOU Zhen,JIANG Hong.Role of Adipose Tissue in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(3):224.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.008]
点击复制

脂肪组织在心房颤动中的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年3期
页码:
224
栏目:
综述
出版日期:
2023-03-25

文章信息/Info

Title:
Role of Adipose Tissue in Atrial Fibrillation
作者:
周振 江洪
(武汉大学人民医院心内科 自主神经调控湖北省重点实验室 武汉大学心脏自主神经研究中心 武汉大学泰康生命医学中心 武汉大学心血管病研究所 心血管病湖北省重点实验室,湖北 武汉 430060)
Author(s):
ZHOU Zhen JIANG Hong
(Department of Cardiology, Renmin Hospital of Wuhan University;Hubei Key Laboratory of Autonomic Nervous System Modulation;Cardiac Autonomic Nervous System Research Center of Wuhan University;Taikang Center for Life and Medical Sciences,Wuhan University;Institute of Molecular Medicine,Renmin Hospital of Wuhan University;Cardiovascular Research Institute,Wuhan University;Hubei Key Laboratory of Cardiology,Wuhan 430060,Hubei,China)
关键词:
脂肪组织心房颤动心外膜脂肪组织自主神经炎症
Keywords:
Adipose tissueAtrial fibrillationEpicardial adipose tissueAutonomic nervous systemInflammation
DOI:
10.16806/j.cnki.issn.1004-3934.2023.03.008
摘要:
肥胖及脂肪组织功能紊乱是心血管疾病的重要危险因素,可促进心房颤动的发生与发展。脂肪组织相关因素导致心房颤动的潜在机制尚不完全明确,其可能机制涉及炎症、自主神经失平衡和心房结构重构等。现综述近年来以心外膜脂肪组织为代表的脂肪组织通过多途径影响心肌细胞和心脏电活动,并提出潜在干预手段靶向调控脂肪组织及其微环境,有望为心房颤动的防治带来新方向。
Abstract:
Obesity and adipose tissue dysfunction are important risk factors for cardiovascular disease. They can contribute to the development and progress of atrial fibrillation. The underlying mechanism of adipose tissue-related factors leading to atrial fibrillation is not completely clear. Its possible mechanism involves inflammation,autonomic nerve imbalance and atrial structural remodeling. In this review,the adipose tissue represented by epicardial adipose tissue in recent years affects cardiac myocytes and cardiac electrical activity through multiple channels,and proposes potential intervention means to target and control adipose tissue and its microenvironment,which is expected to bring new directions for the prevention and treatment of atrial fibrillation

参考文献/References:

[1] Powell-Wiley TM,Poirier P,Burke LE,et al. Obesity and cardiovascular disease:a scientific statement from the American Heart Association[J]. Circulation,2021,143(21):e984-e1010.

[2] Gawa?ko M,Saljic A,Li N,et al. Adiposity-associated atrial fibrillation:molecular determinants,mechanisms and clinical significance[J]. Cardiovasc Res,2022 Jun 11:cvac093.

[3] Yamaguchi Y,Cavallero S,Patterson M,et al. Adipogenesis and epicardial adipose tissue:a novel fate of the epicardium induced by mesenchymal transformation and PPARγ activation[J]. Proc Natl Acad Sci U S A,2015,112(7):2070-2075.

[4] Ernault AC,Meijborg VMF,Coronel R. Modulation of cardiac arrhythmogenesis by epicardial adipose tissue:JACC state-of-the-art review[J]. J Am Coll Cardiol,2021,78(17):1730-1745.

[5] Nalliah CJ,Bell JR,Raaijmakers AJA,et al. Epicardial adipose tissue accumulation confers atrial conduction abnormality[J]. J Am Coll Cardiol,2020,76(10):1197-1211.

[6] Zhu J,Yang Z,Chen X,et al. A stronger association of epicardial fat volume with non-valvular atrial fibrillation than measures of general obesity in Chinese patients undergoing computed tomography coronary angiography[J]. Diabetes Metab Syndr Obes,2021,14:1223-1232.

[7] Nakanishi K,Fukuda S,Tanaka A,et al. Peri-atrial epicardial adipose tissue is associated with new-onset nonvalvular atrial fibrillation[J]. Circ J,2012,76(12):2748-2754.

[8] Chen J,Mei Z,Yang Y,et al. Epicardial adipose tissue is associated with higher recurrence risk after catheter ablation in atrial fibrillation patients:a systematic review and meta-analysis[J]. BMC Cardiovasc Disord,2022,22(1):264.

[9] Ciuffo L,Nguyen H,Marques MD,et al. Periatrial fat quality predicts atrial fibrillation ablation outcome[J]. Circ Cardiovasc Imaging,2019,12(6):e008764.

[10] Dereli S,Bayramo?lu A,Yontar OC,et al. Epicardial fat thickness:a new predictor of successful electrical cardioversion and atrial fibrillation recurrence[J]. Echocardiography,2018,35(12):1926-1931.

[11] Pabon MA,Manocha K,Cheung JW,et al. Linking arrhythmias and adipocytes:insights,mechanisms,and future directions[J]. Front Physiol,2018,9:1752.

[12] Rix TA,Dinesen P,Lundbye-Christensen S,et al. Omega-3 fatty acids in adipose tissue and risk of atrial fibrillation[J]. Eur J Clin Invest,2022,52(1):e13649.

[13] Kornej J,Lin H,Trinquart L,et al. Neck circumference and risk of incident atrial fibrillation in the Framingham Heart Study[J]. J Am Heart Assoc,2022,11(4):e022340.

[14] Yu L,Wang Y,Zhou X,et al. Leptin injection into the left stellate ganglion augments ischemia-related ventricular arrhythmias via sympathetic nerve activation[J]. Heart Rhythm,2018,15(4):597-606.

[15] Zhou Z,Li S,Sheng X,et al. Interactions between metabolism regulator adiponectin and intrinsic cardiac autonomic nervous system:a potential treatment target for atrial fibrillation[J]. Int J Cardiol,2020,302:59-66.

[16] Dobrev D,Heijman J,Hiram R,et al. Inflammatory signalling in atrial cardiomyocytes:a novel unifying principle in atrial fibrillation pathophysiology[J]. Nat Rev Cardiol,2022 Sep 15:1-23.

[17] Couselo-Seijas M,Rodríguez-Ma?ero M,González-Juanatey JR,et al. Updates on epicardial adipose tissue mechanisms on atrial fibrillation[J]. Obes Rev,2021,22(9):e13277.

[18] Wang Q,Shen H,Min J,et al. YKL-40 is highly expressed in the epicardial adipose tissue of patients with atrial fibrillation and associated with atrial fibrosis[J]. J Transl Med,2018,16(1):229.

[19] Kourliouros A,Karastergiou K,Nowell J,et al. Protective effect of epicardial adiponectin on atrial fibrillation following cardiac surgery[J]. Eur J Cardiothorac Surg,2011,39(2):228-232.

[20] Samanta R,Pouliopoulos J,Thiagalingam A,et al. Role of adipose tissue in the pathogenesis of cardiac arrhythmias[J]. Heart Rhythm,2016,13(1):311-320.

[21] Jian B,Li Z,Wang J,et al. Correlation analysis between heart rate variability,epicardial fat thickness,visfatin and AF recurrence post radiofrequency ablation[J]. BMC Cardiovasc Disord,2022,22(1):65.

[22] Abe I,Teshima Y,Kondo H,et al. Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation[J]. Heart Rhythm,2018,15(11):1717-1727.

[23] Abed HS,Samuel CS,Lau DH,et al. Obesity results in progressive atrial structural and electrical remodeling:implications for atrial fibrillation[J]. Heart Rhythm,2013,10(1):90-100.

[24] Fox CS,Gona P,H offmann U,et al. Pericardial fat,intrathoracic fat,and measures of left ventricular structure and function:the Framingham Heart Study[J]. Circulation,2009,119(12):1586-1591.

[25] Mancio J,Azevedo D,Fragao-Marques M,et al. Meta-analysis of relation of epicardial adipose tissue volume to left atrial dilation and to left ventricular hypertrophy and functions[J]. Am J Cardiol,2019,123(3):523-531.

[26] Mancio J,Sousa-Nunes F,Martins R,et al. Decoding the radiomic and proteomic phenotype of epicardial adipose tissue associated with adverse left atrial remodelling and post-operative atrial fibrillation in aortic stenosis[J]. Eur Heart J Cardiovasc Imaging,2022,23(9):1248-1259.

[27] Ardissino M,McCracken C,Bard A,et al. Pericardial adiposity is independently linked to adverse cardiovascular phenotypes:a CMR study of 42 598 UK Biobank participants[J]. Eur Heart J Cardiovasc Imaging,2022,23(11):1471-1481.

[28] Shaihov-Teper O,Ram E,Ballan N,et al. Extracellular vesicles from epicardial fat facilitate atrial fibrillation[J]. Circulation,2021,143(25):2475-2493.

[29] Ernault AC,Verkerk AO,Bayer JD,et al. Secretome of atrial epicardial adipose tissue facilitates reentrant arrhythmias by myocardial remodeling[J]. Heart Rhythm,2022,19(9):1461-1470.

[30] Viviano A,Yin X,Zampetaki A,et al. Proteomics of the epicardial fat secretome and its role in post-operative atrial fibrillation[J]. Europace,2018,20(7):1201-1208.

[31] Zhao L,Ma Z,Guo Z,et al. Analysis of long non-coding RNA and mRNA profiles in epicardial adipose tissue of patients with atrial fibrillation[J]. Biomed Pharmacother,2020,121:109634.

[32] Katritsis DG,Pokushalov E,Romanov A,et al. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation:a randomized clinical trial[J]. J Am Coll Cardiol,2013,62(24):2318-2325.

[33] Garabelli P,Stavrakis S,Kenney JFA,et al. Effect of 28-mm cryoballoon ablation on major atrial ganglionated plexi[J]. JACC Clin Electrophysiol,2018,4(6):831-838.

[34] Li B,Po SS,Zhang B,et al. Metformin regulates adiponectin signalling in epicardial adipose tissue and reduces atrial fibrillation vulnerability[J]. J Cell Mol Med,2020,24(14):7751-7766.

[35] Soucek F,Covassin N,Singh P,et al. Effects of atorvastatin(80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation[J]. Am J Cardiol,2015,116(9):1443-1446.

[36] Mahajan R,Lau DH,Brooks AG,et al. Atrial fibrillation and obesity:reverse remodeling of atrial substrate with weight reduction[J]. JACC Clin Electrophysiol,2021,7(5):630-641.

[37] Conte M,Petraglia L,Cabaro S,et al. Epicardial adipose tissue and cardiac arrhythmias:focus on atrial fibrillation[J]. Front Cardiovasc Med,2022,9:932262.

[38] Colonetti T,Grande AJ,Amaral MC,et al. Effect of exercise on epicardial adipose tissue in adults:a systematic review and meta-analyses[J]. Heart Fail Rev,2021,26(6):1399-1411.

[39] Saco-Ledo G,Valenzuela PL,Castillo-García A,et al. Physical exercise and epicardial adipose tissue:a systematic review and meta-analysis of randomized controlled trials[J]. Obes Rev,2021,22(1):e13103.

[40] Yu L,Scherlag BJ,Dormer K,et al. Autonomic denervation with magnetic nanoparticles[J]. Circulation,2010,122(25):2653-2659.

[41] Yu L,Scherlag BS,Dormer K,et al. Targeted ganglionated plexi denervation using magnetic nanoparticles carrying calcium chloride payload[J]. JACC Clin Electrophysiol,2018,4(10):1347-1358.

[42] Wang H,Zhang Y,Xin F,et al. Calcium-induced autonomic denervation in patients with post-operative atrial fibrillation[J]. J Am Coll Cardiol,2021,77(1):57-67.

[43] Lo LW,Chang HY,Scherlag BJ,et al. Temporary suppression of cardiac ganglionated plexi leads to long-term suppression of atrial fibrillation:evidence of early autonomic intervention to break the vicious cycle of “AF begets AF”[J]. J Am Heart Assoc,2016,5(7):e003309.

[44] Zhang S,Wang M,Jiao L,et al. Ultrasound-guided injection of botulinum toxin type A blocks cardiac sympathetic ganglion to improve cardiac remodeling in a large animal model of chronic myocardial infarction[J]. Heart Rhythm,2022,19(12):2095-2104.

[45] Couselo-Seijas M,López-Canoa JN,Agra-Bermejo RM,et al. Cholinergic activity regulates the secretome of epicardial adipose tissue:association with atrial fibrillation[J]. J Cell Physiol,2019,234(7):10512-10522.

[46] Romanov A,Pokushalov E,Ponomarev D,et al. Long-term suppression of atrial fibrillation by botulinum toxin injection into epicardial fat pads in patients undergoing cardiac surgery:three-year follow-up of a randomized study[J]. Heart Rhythm,2019,16(2):172-177.

相似文献/References:

[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
 HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
 DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
 ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
 ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
 HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
 WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
 XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
 ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
 WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
 ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(3):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]

更新日期/Last Update: 2023-04-24